Clinical Evidence of Nasal High-Flow Therapy in Chronic Obstructive Pulmonary Disease Patients

Judith Elshof*, Marieke L Duiverman

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    7 Citations (Scopus)
    44 Downloads (Pure)

    Abstract

    Nasal high-flow therapy (NHFT) is an upcoming treatment for chronic obstructive pulmonary disease (COPD) patients. It supplies heated, humidified, and, desirably, oxygen-enriched air through a nasal cannula at flow rates up to 60 L/min. Several studies examined the effect of NHFT in COPD patients, but a clear overview is lacking. The present review aimed to give an overview of the clinical evidence of NHFT in 3 aspects of COPD care: long-term use in stable COPD patients, use for treatment of COPD exacerbations, and use during exercise therapy in COPD. For each topic, a specific literature search was performed up to December 9, 2019. Studies show promising results, with most evidence for its long-term use in hypoxemic COPD patients that frequently exacerbate, and very limited evidence for its use during COPD exacerbations or as a worthwhile adjunct to exercise training. More evidence is therefore needed to know how to incorporate NHFT in standard clinical practice.

    Original languageEnglish
    Pages (from-to)140-153
    Number of pages14
    JournalRespiration
    Volume99
    Issue number2
    Early online date28-Jan-2020
    DOIs
    Publication statusPublished - 2020

    Keywords

    • Nasal high-flow therapy
    • Chronic obstructive pulmonary disease
    • Long-term treatment
    • Exacerbation
    • Exercise training
    • POSITIVE-PRESSURE VENTILATION
    • HYPERCAPNIC RESPIRATORY-FAILURE
    • TERM HUMIDIFICATION THERAPY
    • CANNULA OXYGEN-THERAPY
    • NONINVASIVE VENTILATION
    • COPD PATIENTS
    • EXERCISE
    • EXACERBATIONS
    • MULTICENTER
    • EFFICACY

    Cite this